Research has shown that GW0742 may: Enhance mitochondrial -oxidation and overall energy expenditure, particularly within skeletal muscle tissue, as observed in rodent models Improve insulin sensitivity and glucose homeostasis, contributing to favorable metabolic outcomes in experimental models of insulin resistance and Type 2 diabetes Attenuate adipose tissue accumulation, even under high-fat dietary conditions, indicating potential utility in models of diet-induced obesity Downregulate pro-inflammatory cytokine expression, supporting its investigation in inflammation-related disease models Modulate endothelial function and vascular tone, with implications for preclinical research in cardiovascular and metabolic vascular dysfunction GW0742 is not an androgen receptor modulator or SARM, but is often studied alongside such compounds due to its effects on body composition, endurance, and metabolic efficiency
4.1 Trial evidence: recording and limitations of taste-related outcomes in RCTs and PROs In randomised controlled trials (RCTs), primary outcomes are typically focused on body weight and metabolic endpoints, whereas eating-experience-related outcomes are rarely included as prespecified measures and are more often captured only sporadically as adverse events (AEs) (69)
Lemogne C, Delaveau P, Freton M, Guionnet S, Fossati P
After 4 months, the anagen/telogen hair ratio was significantly higher in the treated group than in the placebo group [25,108,109]
